John Crowley Latest Insider Activity
Management EfficiencyThe company has return on total asset (ROA) of (25.62) % which means that it has lost $25.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (82.89) % meaning that it created substantial loss on money invested by shareholders.
Entity SummaryAmicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 325 people.Amicus Therapeutics (FOLD) is traded on BATS Exchange in USA. It is located in New Jersey U.S.A and employs 325 people. Amicus Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.
Amicus Therapeutics Leadership Team
Stock Performance Indicators